VisionGate is dedicated to saving lives through early cancer detection and prevention. The Cell-CT™ is a revolutionary automated 3D cell imaging platform that generates high-resolution 3D biosignatures from intact cells.
VisionGate aims to dramatically improve patient health with the world’s first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. Additional diagnostic tests for gastroesophageal reflux disease (GERD), bladder cancer and other cancer types will follow.
Focused on the World’s Deadliest Cancers
Why is VisionGate starting with lung cancer? It’s one of the world’s biggest killers. In 2010 nearly 160,000 people will die in the United States from lung cancer; more people die of lung cancer than of colon, breast, and prostate cancers combined (American Cancer Society).
“Lung cancer is the leading cause of cancer death throughout the world. It is estimated that well over a million new cases will be diagnosed per year globally, and despite intensive research efforts the prognosis is still poor. In best case scenarios only about 15% of the patients will survive 5 years after primary diagnosis. The reason for the poor prognosis is late diagnosis and lack of efficient treatment of systemic disease. In two-thirds of the cases, lung cancer has already spread to regional lymph nodes or beyond at the time of initial diagnosis.” (International Association for the Study of Lung Cancer)
Tobacco smoking is by far the leading cause of lung cancer, with more than 87% of lung cancers caused directly by smoking (American Cancer Society). In the U.S. alone, more than 90 million people are at elevated risks for lung cancer because they are current or former smokers. Worldwide, there are approximately 1.3 billion current smokers.
VisionGate was incorporated in 2001 and is committed to applying its technologies to the early detection of lung cancer.